Zealand Pharma A/S has begun treating the first patient in a Phase II proof-of-concept study of danegaptide. Danegaptide is a novel dipeptide with potential as a first-in-class medicinal treatment to reduce tissue damage caused by reperfusion. The objective of this Phase II study is to assess the efficacy and safety of danegaptide in reducing tissue damage from reperfusion injuries in patients with an acute myocardial infarction (ST-segment elevation myocardial infarction, or STEMI) when added ...